Table 1 The descriptive characteristics of included studies
First Author | Published Year | Study Period | Study location | Area | Age | Sample Size | Positive | HSV-2 Testing | Study Design | Sampling Procedure | QATSO |
|---|---|---|---|---|---|---|---|---|---|---|---|
Xi Chen [24] | 2015 | 2009.08-2009.11 | Changsha | Central China | ≥ 16, 83% under 35 years | 826 | 113 | Antibody | Cross-sectional | Venue-based, Snowball, internet | Satisfactory |
Yingying Ding [25] | 2017 | 2014.05-2014.12 | Shanghai | Eastern China | 18–45 87.33% under 35 years | 243 | 23 | Antibody | Cross-sectional | NGOa, VCTb | Good |
Yuji Feng [10] | 2010 | 2007.03-2007.07 | Chengdu | Southwest China | 16–45 Median age:24 57.5% under 25 years | 538 | 133 | Antibody | Cross-sectional | Snowball | Good |
Zhenqiu Liu [26] | 2017 | 2013.12-2014.12 | Shanghai | Eastern China | Mean age: 34.09(SD = 9.85) 51.6% under 30 years | 333 | 67 | Antibody | Cross-sectional | Venue-based | Satisfactory |
Junjie Xu [27] | 2016 | 2012.06-2013.06 | Shanghai, Nanjing, Changsha, Zhengzhou, Ji’nan, Shenyang, Kunming | Multi-region | ≥ 18, 77.5% under 35 years | 4415 | 552 | Antibody | Cross-sectional | Internet, Venue-based, Peer referrals | Good |
Hongjing Yan [28] | 2016 | 2008.05-2008.08, 2012.09-2012.12 | Nanjing | Eastern China | ≥ 18, 66.3%(2008),58.7%(2012) under 30 years | 1019 | 137 | Antibody | Cross-sectional | Respondent-driven | Good |
Yueping Yin [29] | 2012 | 2009.07-2010.05 | Shenzhen, Guangzhou, Changzhou | Southern China | Mean age:30.14 Median age:29 Age range: 18–66 59.6% Under 35 years | 1462 | 234 | Antibody | Cross-sectional | STDc clinic, Health center, Venus-based | Satisfactory |
Ning Zhao [30] | 2019 | 2018.03-2018.10 | Shenyang | Northeast China | ≥ 18, 77% Over 25 years | 183 | 2 | PCR | Cross-sectional | VCT | Satisfactory |
ShaSha Mao [9] | 2021 | 2012,2014, 2016,2018 | Shenzhen | Southern China | Mean age:31.5(SD = 8.38) 70.2% Under 35 years | 1695 | 268 | Antibody | Cross-sectional | Time-location sampling | Good |
Ningxiao Cao [31] | 2006 | 2003.03-2003.07 | Jiangsu (No city specified) | Eastern China | Mean age:32.68(SD = 10.6) Age range:19–77 66.66% Under 35 years | 90 | 7 | Antibody | Cross-sectional | Venue-based | Satisfactory |
Xianbin Ding [32] | 2010 | 2008.02-2008.06 | Chongqing | Southwest China | Mean age:26.3(SD = 7.1) Age range:18–67 64.7% Under 30 years | 743 | 25 | Antibody | Cross-sectional | Snowball | Satisfactory |
Aiping Fan [33] | 2017 | 2015.05-2016.04 | Taian | Eastern China | Mean age:21.1(SD = 1.8) Age range:17–27 | 127 | 4 | Antibody | Cross-sectional | VCT | Satisfactory |
Jie Gao [34] | 2013 | 2010.10-2010.12 | Dehong | Southern China | Not available | 88 | 3 | Antibody | Cross-sectional | Internet, Venue-based | Satisfactory |
Yanjie Gao [35] | 2012 | 2009.08-2012.12 | Beijing | Northern China | Median age:27 Age range:18–71 | 962 | 51 | Antibody | Cross-sectional | Internet, Peer referrals | Satisfactory |
Xiuyun Han [36] | 2015 | 2013.04-2013.06 | Ji’nan | Eastern China | Age range:17–59 85% Under 40 years | 400 | 37 | Antibody | Cross-sectional | Internet, Peer referrals | Satisfactory |
Yin Han [37] | 2020 | 2015,2016, 2017 | Ji’nan | Eastern China | ≥ 16, Mean age:30.21(SD = 9.38) Age range:16–73 84.1% Under 40 years | 1300 | 73 | Antibody | Cross-sectional | Snowball | Satisfactory |
Guanghua Lan [38] | 2013 | 2009–2010 | Nanning | Southern China | ≥ 18, Mean age:28.1 | 291 | 35 | Antibody | Cohort | Snowball | Good |
Pai Liu [39] | 2013 | 2008.09-2009.02 | Nanjing, Yangzhou, Wuxi, Changzhou, Suzhou | Eastern China | Mean age:30.48 Age range:18–67 | 388 | 38 | Antibody | Cross-sectional | Venue-based | Satisfactory |
Ying Liu [40] | 2017 | 2015.03-2015.08 | Shanghai | Eastern China | ≥ 18, Mean age:29.4 83.9% Under 35 years | 732 | 41 | Antibody | Cross-sectional | VCT | Good |
Chunru Lu [41] | 2019 | 2015.06-2018.06 | Shenzhen | Southern China | ≥ 18, 71.19% Under 30 years | 1604 | 34 | Antibody | Cross-sectional | STD clinic | Satisfactory |
Yanmin Ma [42] | 2016 | 2014.12-2015.01 | Zhengzhou | Central China | Mean age:31.6(SD = 9.4) Age range:17–76 82.87% Under 40 years | 467 | 53 | Antibody | Cross-sectional | Snowball | Good |
Xiangdong Min [43] | 2013 | 2012.07-2012.12 | Kunming | Southwest China | ≥ 16, Mean age:29 Age range:19–38 | 458 | 71 | Antibody | Cross-sectional | Internet, Peer referrals | Satisfactory |
Ji Peng [44] | 2020 | 2019.02-2019.09 | Changsha | Central China | ≥ 18, 95.67% Under 40 years | 462 | 14 | Antibody | Cross-sectional | Respondent-driven | Satisfactory |
Ou Qin [45] | 2013 | 2009.07-2009.09 | Guiyang | Southwest China | ≥ 18, Mean age:25.8(SD = 6.5) 58.06% Under 25 years | 341 | 22 | Antibody | Cross-sectional | Snowball | Satisfactory |
Huiqin Ren [46] | 2012 | NR | Urumqi | Northwest China | ≥ 18 | 300 | 14 | Antibody | Cohort | Snowball | Good |
Jue Wang [47] | 2012 | 2009.05-2009.07 | Beijing, Shanghai, Kunming, Guiyang. Chongqing, Chengdu, Urumqi, Nanning | Multi-region | ≥ 18 Age range:18–69 | 3227 | 344 | Antibody | Cross-sectional | Snowball | Satisfactory |
Hongyi Wei [48] | 2014 | 2009.05-2012.05 | Shenyang | Northeast China | Age range:17–75 59% Under 30 years | 307 | 54 | Antibody | Cross-sectional | STD clinic | Satisfactory |
Zongze Xie [49] | 2021 | 2019.01-2019.12 | Taizhou | Eastern China | ≥ 18, 67.14% Under 30 years | 837 | 45 | Antibody | Cross-sectional | Internet, Venue-based | Satisfactory |
Yu Zhang [50] | 2021 | 2018.10-2019.08 | Guiyang | Southwest China | Age range:15–66 84.9% Under 30 years | 577 | 74 | Antibody | Cross-sectional | Respondent-driven | Satisfactory |
Liangjia Zhou [51] | 2016 | 2013.04-2013.08 | Nanjing | Eastern China | Not available | 370 | 62 | Antibody | Cohort | Snowball, Peer referrals | Satisfactory |
Weiming Zhu [52] | 2008 | 2007.11-2007.12 | Taizhou | Eastern China | Mean age:27.9(SD = 6) Age range:18–48 67.9% Under 30 years | 73 | 11 | Antibody | Cross-sectional | Convenient, Venue-based | Good |